Synthesis and Feasibility Evaluation of a new Trastuzumab Conjugate Integrated with Paclitaxel and (89)Zr for Theranostic Application Against HER2‐Expressing Breast Cancers

The preparation and in  vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)‐chelated (89)Zr have been reported. These comounds have potential applications against HER2 receptor positive breast cancers. We conjugated DFO and PTX to trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Joo Hee, Han, Sang Jin, Kim, Jung Young, Kim, Kwang Il, Lee, Kyo Chul, Kang, Chi Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454217/
https://www.ncbi.nlm.nih.gov/pubmed/31008009
http://dx.doi.org/10.1002/open.201900037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454217/
https://www.ncbi.nlm.nih.gov/pubmed/31008009
http://dx.doi.org/10.1002/open.201900037

Ejemplares similares